1-833-ZEPOSIA
ZEPOSIA is a once-daily pill for adults with relapsing multiple sclerosis (MS).
Take as directed by your doctor if certain liver problems exist.
ZEPOSIA is a once-daily pill for adults with relapsing multiple sclerosis (MS).
Take as directed by your doctor if certain liver problems exist.
Explore the results below to see how ZEPOSIA performed. ZEPOSIA was compared to a leading injectable medicine, Avonex® (interferon beta-1a), in two separate clinical studies
People had fewer relapses with ZEPOSIA
People taking ZEPOSIA had an Annualized Relapse Rate (ARR) of 0.181 vs 0.350 with a leading injectable.
A total of 895 people were in this study (ZEPOSIA 447, a leading injectable 448).
ARR is the average number of relapses a group of people has in one year.
People taking ZEPOSIA had an Annualized Relapse Rate (ARR) of 0.172 vs 0.276 with a leading injectable.
A total of 874 people were in this study (ZEPOSIA 433, a leading injectable 441).
ARR is the average number of relapses a group of people has in one year.
More people were relapse free*
A total of 895 people were in this study (ZEPOSIA 447, a leading injectable 448).
*A relapse was defined as new or worsening symptoms directly associated with MS that lasted more than twenty-four hours (after having a mostly stable neurological state for at least thirty days).
A total of 874 people were in this study (ZEPOSIA 433, a leading injectable 441).
*A relapse was defined as new or worsening symptoms directly associated with MS that lasted more than twenty-four hours (after having a mostly stable neurological state for at least thirty days).
This progression was confirmed after 3 months with predefined increases in Expanded Disability Status Scale A method used to measure disability in MS and monitor changes in the level of disability over time. scores and results were combined from both clinical studies.
Fewer new or enlarging lesions (T2) in both studies
T2 (lesions) refers to a type of magnetic resonance imaging (MRI) scan (a T2-weighted image) that can be used to identify the total number of lesions a person has.
People taking ZEPOSIA had an average of 1.47 lesions (T2) vs 2.84 with a leading injectable.
A total of 895 people were in this study (ZEPOSIA 447, a leading injectable 448).
People taking ZEPOSIA had an average of 1.84 lesions (T2) vs 3.18 with a leading injectable.
A total of 874 people were in this study (ZEPOSIA 433, a leading injectable 441).
Fewer lesions showing active inflammation (T1 Gd-enhancing)
T1 Gadolinium (Gd)-enhancing lesions are areas of active inflammation that show current MS activity in the brain.
People taking ZEPOSIA had an average of 0.16 lesions (T1 Gd-enhancing) vs 0.43 with a leading injectable.
A total of 895 people were in this study (ZEPOSIA 447, a leading injectable 448).
People taking ZEPOSIA had an average of 0.18 lesions (T1 Gd-enhancing) vs 0.37 with a leading injectable.
A total of 874 people were in this study (ZEPOSIA 433, a leading injectable 441).
I’ve been taking ZEPOSIA for a year now, and my doctor and I are happy with my results.
—Melissa
A real ZEPOSIA patient compensated for her time.
(Individual results may vary.)
See the side effects that were reported in clinical trials.
Explore safetyIn two separate clinical studies, a one-year and a two-year study, ZEPOSIA was compared to a leading injectable medicine, Avonex.
Both studies were randomized, meaning participants were chosen randomly to receive either ZEPOSIA or a leading injectable medicine. The studies were also double-blind, so neither the professionals giving the medication nor the people taking it knew which medication was being administered.
Study size
The two clinical studies, when combined, were one of the largest studies to compare one MS medication to another (not a placebo).
Together, the two studies included 1,769 people in total:
Who was studied
Prior to joining the study, all participants experienced at least one relapse within the past two years and had evidence of T1 Gd-enhancing lesions. T1 Gd-enhancing lesions are areas of active inflammation that show current MS activity in the brain.
The average age across both studies was
In both studies combined, approximately